Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis
A Study to Assess the Safety and Tolerability of Anti-MIF Antibody in Subjects With Lupus Nephritis
Sponsor: Baxalta now part of Shire
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Baxalta now part of Shire
- Hemophilia B · Phase PHASE1/PHASE2 · May 2021
- Graft Versus Host Disease · Phase PHASE2/PHASE3 · May 2018
- Metastatic Colorectal Cancer · Phase PHASE2 · Feb 2017
- Refractory Ovarian Cancer With Recurrent Symptomatic Malignant Ascites · Phase PHASE1/PHASE2 · May 2016
- Sickle Cell Disease · Phase PHASE2 · Mar 2015
Other Systemic Lupus Erythematosus trials with similar outcome
This PHASE1 trial investigates Systemic Lupus Erythematosus and is currently terminated or withdrawn. Baxalta now part of Shire leads this study, which shows 9 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jun 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jun 2021 [monthly]
Terminated PHASE1
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1
-
Nov 2017 — Jun 2018 [monthly]
Terminated PHASE1
-
Feb 2017 — Nov 2017 [monthly]
Terminated PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1
First recorded
Nov 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Baxalta now part of Shire
For direct contact, visit the study record on ClinicalTrials.gov .